E
EpiEP
Medical device startup developing a novel access system to the pericardium of the heart
About EpiEP
EpiEP Inc. is a medical device company established in 2008, operating in the surgical and electrophysiology device market. The company is focused on developing instruments for minimally invasive procedures on the surface of the heart, an approach considered a significant advancement in electrophysiology. EpiEP's core business revolves around the sale of its proprietary EpiAccess™ System to healthcare facilities. This system is designed for use by physicians performing epicardial access procedures to treat conditions like ventricular tachycardia (VT) and atrial fibrillation (AF).
The company was founded by George T. Gillies, Ph.D., and Dr. Srijoy Mahapatra. Pamela Bunes, the current Chief Executive Officer, brings 24 years of experience in the medical device industry, with significant tenures at Johnson & Johnson's Ethicon Endo-Surgery and Biosense Webster. Her background includes managing new product launches, securing FDA and CE Mark approvals, and raising capital, with a recent decade focused specifically on cardiology and electrophysiology.
The company's flagship product, the EpiAccess™ System, provides a safer and more precise method for accessing the pericardial space surrounding the heart. The system consists of a disposable, single-use Tuohy-style needle with an integrated fiber optic pressure sensor at its tip, and a reusable control unit with a display monitor. A key feature is the pressure-guided needle that provides real-time data to alert physicians of the needle tip's exact location, a critical factor in avoiding unintended punctures of the heart muscle. This technology is designed to work in conjunction with standard fluoroscopy, offering adjunctive data to confirm when the needle has entered the pericardial cavity. The system received CE Mark approval in March 2014 and FDA 510(k) clearance in October 2014.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2015 | $8.6M | $34M | Undisclosed | — |
| LATE VC✓Equity / VC | Jun 2013 | $4.1M | $16M | Undisclosed | — |
Growth signals
Latest recorded traffic for EpiEP is 950 monthly website visits, up 763.6% over the last three months. EpiEP's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
LaunchCapital
Other known investors2 additional known investors
Lucas Point Ventures
University of Virginia Seed Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EpiEP on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EpiEP’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







